Tvardi Therapeutics (69C) Stock Forecast & Price Target

Compare

1 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

69C Analyst Ratings

Strong Buy

5 Buy

0 Hold

0 Sell

Based on 5 analysts giving stock ratings to

Tvardi

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

69C Stock 12 Month Forecast

Average Price Target

€51.80

▲(53.48% Upside)

Based on 5 Wall Street analysts offering 12 month price targets for Tvardi Therapeutics in the last 3 months. The average price target is €51.80 with a high forecast of €66.67 and a low forecast of €39.32. The average price target represents a 53.48% change from the last price of €33.75.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"€7","22":"€22","37":"€37","52":"€52","67":"€67"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":66.67128234,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€66.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":51.798457818,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€51.80</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":39.31896138,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€39.32</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,22,37,52,67],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,32.55,35.17471402615384,37.79942805230769,40.424142078461536,43.04885610461538,45.67357013076923,48.298284156923074,50.92299818307693,53.54771220923077,56.17242623538462,58.79714026153846,61.42185428769231,64.04656831384617,{"y":66.67128234,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,32.55,34.030650601384615,35.51130120276923,36.99195180415384,38.47260240553846,39.95325300692308,41.433903608307695,42.91455420969231,44.39520481107692,45.87585541246154,47.35650601384616,48.83715661523077,50.31780721661539,{"y":51.798457818,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,32.55,33.070689336923074,33.59137867384615,34.11206801076923,34.632757347692305,35.15344668461538,35.67413602153846,36.194825358461536,36.71551469538461,37.23620403230769,37.75689336923077,38.277582706153844,38.79827204307692,{"y":39.31896138,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":18.449,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.8,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.985,"date":1730419200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":8.964,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":14.507,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":14.507,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":14.507,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.78,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.5,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.2,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.1,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.15,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.55,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€66.67

Average Price Target€51.80

Lowest Price Target€39.32

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Jay Olson

Oppenheimer

€55.43

Buy

64.25%

Upside

Reiterated

10/01/25

Oppenheimer Sticks to Their Buy Rating for Tvardi Therapeutics (TVRD)

Ryan Deschner

Raymond James

€27.14→€52.88

Buy

56.67%

Upside

Reiterated

09/10/25

Analysts Are Bullish on These Healthcare Stocks: BioMarin Pharmaceutical (BMRN), Black Diamond Therapeutics (BDTX)

Yasmeen Rahimi

Piper Sandler

€66.52

Buy

97.10%

Upside

Reiterated

09/08/25

Tvardi Therapeutics (TVRD) Receives a Buy from Piper Sandler

Debanjana Chatterjee

JonesTrading

€39.23

Buy

16.24%

Upside

Reiterated

08/28/25

Tvardi Therapeutics: Buy Rating Driven by Promising TTI-101 Trial Prospects

Steven Seedhouse

Cantor Fitzgerald

€44.35

Buy

31.40%

Upside

Initiated

07/11/25

Tvardi Therapeutics initiated with an Overweight at Cantor FitzgeraldTvardi Therapeutics initiated with an Overweight at Cantor Fitzgerald

Julian Harrison

BTIG

€46.91

Buy

38.98%

Upside

Reiterated

05/27/25

Tvardi Therapeutics (TVRD) Gets a Buy from BTIG

Christopher Liu

Lucid Capital

€35.82

Buy

6.13%

Upside

Initiated

04/30/25

Tvardi Therapeutics initiated with a Buy at Lucid CapitalTvardi Therapeutics initiated with a Buy at Lucid Capital

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Jay Olson

Oppenheimer

€55.43

Buy

64.25%

Upside

Reiterated

10/01/25

Oppenheimer Sticks to Their Buy Rating for Tvardi Therapeutics (TVRD)

Ryan Deschner

Raymond James

€27.14→€52.88

Buy

56.67%

Upside

Reiterated

09/10/25

Analysts Are Bullish on These Healthcare Stocks: BioMarin Pharmaceutical (BMRN), Black Diamond Therapeutics (BDTX)

Yasmeen Rahimi

Piper Sandler

€66.52

Buy

97.10%

Upside

Reiterated

09/08/25

Tvardi Therapeutics (TVRD) Receives a Buy from Piper Sandler

Debanjana Chatterjee

JonesTrading

€39.23

Buy

16.24%

Upside

Reiterated

08/28/25

Tvardi Therapeutics: Buy Rating Driven by Promising TTI-101 Trial Prospects

Steven Seedhouse

Cantor Fitzgerald

€44.35

Buy

31.40%

Upside

Initiated

07/11/25

Tvardi Therapeutics initiated with an Overweight at Cantor FitzgeraldTvardi Therapeutics initiated with an Overweight at Cantor Fitzgerald

Julian Harrison

BTIG

€46.91

Buy

38.98%

Upside

Reiterated

05/27/25

Tvardi Therapeutics (TVRD) Gets a Buy from BTIG

Christopher Liu

Lucid Capital

€35.82

Buy

6.13%

Upside

Initiated

04/30/25

Tvardi Therapeutics initiated with a Buy at Lucid CapitalTvardi Therapeutics initiated with a Buy at Lucid Capital

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Tvardi Therapeutics

1 Month

xxx

Success Rate

3/4 ratings generated profit

Average Return

+21.15%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 75.00% of your transactions generating a profit, with an average return of +21.15% per trade.

3 Months

xxx

Success Rate

3/3 ratings generated profit

Average Return

+33.57%

reiterated a xxx

rating 30 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +33.57% per trade.

1 Year

Debanjana ChatterjeeJonesTrading

Success Rate

4/4 ratings generated profit

Average Return

+63.65%

reiterated a buy rating last month

Copying Debanjana Chatterjee's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +63.65% per trade.

2 Years

xxx

Success Rate

4/4 ratings generated profit

Average Return

+63.65%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +63.65% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

69C Analyst Recommendation Trends

Rating

Jun 25

Jul 25

Aug 25

Sep 25

Oct 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 69C has received 7 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. 69C average Analyst price target in the past 3 months is 51.80.

Each month's total comprises the sum of three months' worth of ratings.

69C Financial Forecast

69C Earnings Forecast

Next quarter’s earnings estimate for 69C is -€0.58 with a range of -€1.30 to -€0.24. The previous quarter’s EPS was ―. 69C beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year 69C has Outperformed its overall industry.

69C Sales Forecast

Next quarter’s sales forecast for 69C is €0.00 with a range of €0.00 to €0.00. The previous quarter’s sales results were ―. 69C beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year 69C has Outperformed its overall industry.

69C Stock Forecast FAQ

What is DE:69C’s average 12-month price target, according to analysts?

Based on analyst ratings, Tvardi Therapeutics’s 12-month average price target is 51.80.

What is DE:69C’s upside potential, based on the analysts’ average price target?

Tvardi Therapeutics has 53.48% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Tvardi Therapeutics a Buy, Sell or Hold?

Tvardi Therapeutics has a consensus rating of Strong Buy, which is based on 5 buy ratings, 0 hold ratings and 0 sell ratings.

What is Tvardi Therapeutics’s share price target?

The average share price target for Tvardi Therapeutics is 51.80. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €66.67 ,and the lowest forecast is €39.32. The average share price target represents 53.48% Increase from the current price of €33.75.

What do analysts say about Tvardi Therapeutics?

Tvardi Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.

How can I buy shares of Tvardi Therapeutics?

To buy shares of DE:69C, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Tvardi Therapeutics (69C) Stock Forecast & Price Target

69C Analyst Ratings

69C Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Tvardi Therapeutics

69C Analyst Recommendation Trends

69C Financial Forecast

69C Earnings Forecast

69C Sales Forecast

69C Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts